• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。

Decade-long leukaemia remissions with persistence of CD4 CAR T cells.

机构信息

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.

DOI:10.1038/s41586-021-04390-6
PMID:35110735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9166916/
Abstract

The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers. However, little is known about the long-term potential and clonal stability of the infused cells. Here we studied long-lasting CD19-redirected chimeric antigen receptor (CAR) T cells in two patients with chronic lymphocytic leukaemia who achieved a complete remission in 2010. CAR T cells remained detectable more than ten years after infusion, with sustained remission in both patients. Notably, a highly activated CD4 population emerged in both patients, dominating the CAR T cell population at the later time points. This transition was reflected in the stabilization of the clonal make-up of CAR T cells with a repertoire dominated by a small number of clones. Single-cell profiling demonstrated that these long-persisting CD4 CAR T cells exhibited cytotoxic characteristics along with ongoing functional activation and proliferation. In addition, longitudinal profiling revealed a population of gamma delta CAR T cells that prominently expanded in one patient concomitant with CD8 CAR T cells during the initial response phase. Our identification and characterization of these unexpected CAR T cell populations provide novel insight into the CAR T cell characteristics associated with anti-cancer response and long-term remission in leukaemia.

摘要

经基因重定向以识别肿瘤细胞的 T 淋巴细胞过继转移已被证明具有治疗多种癌症的潜力。然而,对于输注细胞的长期潜在性和克隆稳定性知之甚少。在这里,我们研究了两名在 2010 年获得完全缓解的慢性淋巴细胞白血病患者中持久性的 CD19 重定向嵌合抗原受体 (CAR) T 细胞。输注后超过十年仍可检测到 CAR T 细胞,两名患者均持续缓解。值得注意的是,两名患者均出现高度活化的 CD4 群体,在后期主导 CAR T 细胞群体。这种转变反映在 CAR T 细胞克隆组成的稳定上,其特征是由少数克隆主导的丰富谱。单细胞分析表明,这些长期存在的 CD4 CAR T 细胞具有细胞毒性特征,同时伴有持续的功能激活和增殖。此外,纵向分析显示,在一名患者中,与 CD8 CAR T 细胞同时,γδ CAR T 细胞的一个亚群在初始反应阶段显著扩增。我们对这些意外的 CAR T 细胞群体的鉴定和特征分析为白血病中与抗癌反应和长期缓解相关的 CAR T 细胞特征提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/77f438d5f3bc/nihms-1808198-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/755f7e92dd60/nihms-1808198-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/ff94274acdf4/nihms-1808198-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/bd9b3266f99c/nihms-1808198-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/240ffd30a733/nihms-1808198-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/d1eb3b1ae833/nihms-1808198-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/acf8ab36dc5f/nihms-1808198-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/323a618030a1/nihms-1808198-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/bee0ad2d2c5a/nihms-1808198-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/073878a68ff3/nihms-1808198-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/c35748bffb4d/nihms-1808198-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/d0a6a88b3d8c/nihms-1808198-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/a1a2d125290c/nihms-1808198-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/125140ee88d5/nihms-1808198-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/77f438d5f3bc/nihms-1808198-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/755f7e92dd60/nihms-1808198-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/ff94274acdf4/nihms-1808198-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/bd9b3266f99c/nihms-1808198-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/240ffd30a733/nihms-1808198-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/d1eb3b1ae833/nihms-1808198-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/acf8ab36dc5f/nihms-1808198-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/323a618030a1/nihms-1808198-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/bee0ad2d2c5a/nihms-1808198-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/073878a68ff3/nihms-1808198-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/c35748bffb4d/nihms-1808198-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/d0a6a88b3d8c/nihms-1808198-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/a1a2d125290c/nihms-1808198-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/125140ee88d5/nihms-1808198-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c18/9166916/77f438d5f3bc/nihms-1808198-f0004.jpg

相似文献

1
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
2
CD19 CAR T cell product and disease attributes predict leukemia remission durability.CD19 CAR T 细胞产品和疾病特征可预测白血病缓解的持久度。
J Clin Invest. 2019 Mar 12;129(5):2123-2132. doi: 10.1172/JCI125423. Print 2019 May 1.
3
In Vivo Generation of CAR T Cells Selectively in Human CD4 Lymphocytes.在人 CD4 淋巴细胞中选择性生成嵌合抗原受体 T 细胞。
Mol Ther. 2020 Aug 5;28(8):1783-1794. doi: 10.1016/j.ymthe.2020.05.005. Epub 2020 May 16.
4
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.抗CD19嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病:一项系统评价和荟萃分析。
Lancet Haematol. 2020 Nov;7(11):e816-e826. doi: 10.1016/S2352-3026(20)30277-5.
5
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞疗法的长期随访。
J Clin Oncol. 2020 Nov 10;38(32):3805-3815. doi: 10.1200/JCO.20.01467. Epub 2020 Oct 6.
6
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL:缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
7
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.在接受 CD19 CAR-T 免疫治疗的患者中,CAR-T 细胞的克隆动力学和单细胞转录组分析。
Nat Commun. 2020 Jan 10;11(1):219. doi: 10.1038/s41467-019-13880-1.
8
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.伊布替尼提高慢性淋巴细胞白血病患者嵌合抗原受体 T 细胞产量。
Int J Cancer. 2021 Jan 15;148(2):419-428. doi: 10.1002/ijc.33212. Epub 2020 Jul 28.
9
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.针对中枢神经系统复发或难治性急性淋巴细胞白血病的 CD19 靶向嵌合抗原受体 T 细胞疗法:五项临床试验 pooled data 的事后分析。
Lancet Haematol. 2021 Oct;8(10):e711-e722. doi: 10.1016/S2352-3026(21)00238-6.
10
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.序贯 CD19 和 CD22 嵌合抗原受体 T 细胞治疗儿童难治或复发 B 细胞急性淋巴细胞白血病:单臂、2 期研究。
Lancet Oncol. 2023 Nov;24(11):1229-1241. doi: 10.1016/S1470-2045(23)00436-9. Epub 2023 Oct 17.

引用本文的文献

1
[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus].[CD19嵌合抗原受体T细胞治疗系统性红斑狼疮的疗效及安全性长期随访]
Z Rheumatol. 2025 Sep 4. doi: 10.1007/s00393-025-01705-0.
2
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy.用于联合肿瘤免疫治疗的序贯给药系统的工程策略。
Acta Pharm Sin B. 2025 Aug;15(8):3951-3977. doi: 10.1016/j.apsb.2025.05.039. Epub 2025 Jun 6.
3
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.
自身免疫性疾病中的嵌合抗原受体T细胞疗法:一个充满前景的前沿领域。
Front Immunol. 2025 Aug 12;16:1613878. doi: 10.3389/fimmu.2025.1613878. eCollection 2025.
4
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.基于定向进化发现用于体内重刺激嵌合抗原受体T细胞的配体。
Nat Biomed Eng. 2025 Aug 25. doi: 10.1038/s41551-025-01470-0.
5
Direct visualization of chimeric antigen receptors on primary human T cells using STORM super-resolution microscopy.使用STORM超分辨率显微镜对原代人T细胞上的嵌合抗原受体进行直接可视化。
Front Immunol. 2025 Aug 1;16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.
6
A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy.一种用于CAR T细胞疗法的多尺度半机制性CK/PD模型。
Front Syst Biol. 2024 Aug 29;4:1380018. doi: 10.3389/fsysb.2024.1380018. eCollection 2024.
7
Precision-cut tumor tissue slices, a novel tool to study the tumor microenvironment interactions with chimeric antigen receptor (CAR) T cells.精密切割肿瘤组织切片,一种研究肿瘤微环境与嵌合抗原受体(CAR)T细胞相互作用的新工具。
PLoS One. 2025 Aug 8;20(8):e0327322. doi: 10.1371/journal.pone.0327322. eCollection 2025.
8
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.工程化过继性细胞免疫疗法中生物医学虚拟孪生体的设计规范。
NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.
9
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide.用衔接子嵌合抗原受体T细胞靶向CD276为小细胞肺癌提供了一种新的治疗策略,并防止了CD276依赖性的自相残杀。
J Hematol Oncol. 2025 Jul 28;18(1):76. doi: 10.1186/s13045-025-01729-8.
10
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.嵌合抗原受体自然杀伤T细胞:重新定义细胞免疫疗法的前沿领域。
Front Immunol. 2025 Jul 11;16:1625426. doi: 10.3389/fimmu.2025.1625426. eCollection 2025.